eli lilly glp-1 drug FDA approves new weight-loss pill, Foundayo GLP-1 weight loss could soon

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 17 trials

Employer-sponsored coverage expansion Corporate coverage for GLP-1 medications shows measurable growth patterns

The goal is to help everyone understand the rhythm of gameplay, make informed decisions, and maintain control over both time and budget

Moreover, because patients with T1D were excluded from studies looking at cardiovascular and renal outcomes with the use of GLP-1RA, it remains unknown whether those benefits observed in patients with T2D or obesity without T2D translate to the T1D population